As a proof of concept to assess the immunomodulatory potential of PRP6-HO7 in autoimmune pathologies, we undertook pilot studies in two consecutive small cohorts of SLE patients, mostly with active LN, termed cohort 1 and cohort 2. The gene discussed is PRPF6; the disease is systemic lupus erythematosus.